AstraZeneca antibody drug works to prevent Covid-19 in longer-term studies

The therapy's "real advantage" is as a preventative shot, rather than as a treatment, the drugmaker said



Reuters file
Reuters file

By Reuters

Published: Thu 18 Nov 2021, 11:39 AM

AstraZeneca (AZN.L) said on Thursday its Covid-19 antibody drug was 83 per cent effective in cutting the risk of people contracting symptomatic illness in a six-month follow-up study.

The results have cemented the drugmaker's lead in developing preventative coronavirus treatments.

The Anglo-Swedish company said a separate study in patients with mild-to-moderate Covid-19 showed that a higher dose of the therapy, AZD7442, cut the risk of symptoms worsening by 88 per cent when given within three days of first symptoms.

ALSO READ:

The latest round of positive results potentially position AstraZeneca as a rare supplier of both Covid-19 vaccines and treatments, with the drugmaker having said the therapy's "real advantage" was as a preventative shot, rather than as a treatment.


More news from coronavirus